4//SEC Filing
Bernick Brian 4
Accession 0001209191-22-060588
CIK 0000025743other
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 7:41 PM ET
Size
14.2 KB
Accession
0001209191-22-060588
Insider Transaction Report
Form 4
Bernick Brian
Director
Transactions
- Exercise/Conversion
Common Stock
2022-12-06+3,167→ 5,127 total - Sale
Common Stock
2022-12-09$6.31/sh−320$2,020→ 3,872 total - Sale
Common Stock
2022-12-06$4.92/sh−935$4,602→ 4,192 total - Exercise/Conversion
Restricted Stock Units
2022-12-06−3,167→ 10,517 totalExercise: $0.00→ Common Stock (3,167 underlying)
Holdings
- 35,147(indirect: See Footnote)
Common Stock
- 60(indirect: See Footnote)
Common Stock
Footnotes (6)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs).
- [F2]The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
- [F4]The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The reporting person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F5]The reported securities are owned by the GP. As disclosed in Footnote 4 above, the reporting person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The reporting person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein.
- [F6]The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022.
Documents
Issuer
TherapeuticsMD, Inc.
CIK 0000025743
Entity typeother
Related Parties
1- filerCIK 0001532233
Filing Metadata
- Form type
- 4
- Filed
- Dec 8, 7:00 PM ET
- Accepted
- Dec 9, 7:41 PM ET
- Size
- 14.2 KB